Shopping Cart
Remove All
Your shopping cart is currently empty
GNF362 is an orally available, selective and potent inhibitor of inositol trisphosphate 3'kinase B (ITPKB), inhibits Itpka and Itpkc, overcomes TMZ chemoresistance, and selectively deletes donor allogeneic reactive T-cells.GNF362 reverses the migratory stimulatory effects of ITPKA overexpression.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $399 | 5 days | 5 days |
| Description | GNF362 is an orally available, selective and potent inhibitor of inositol trisphosphate 3'kinase B (ITPKB), inhibits Itpka and Itpkc, overcomes TMZ chemoresistance, and selectively deletes donor allogeneic reactive T-cells.GNF362 reverses the migratory stimulatory effects of ITPKA overexpression. |
| In vitro | GNF362 blocks Ins(1,3,4,5)P4 production, enhances antigen receptor-mediated Ca2+ responses, and leads to apoptosis of activated T cells in an Itpkb-dependent manner, while augmenting SOC responses with an EC50 value of 12 nM[1]. |
| In vivo | In the Lewis rat antigen-induced arthritis (rAIA) model, GNF362 (6 or 20 mg/kg; oral administration; twice daily; 21 days) reduced knee joint swelling in rats by 47% in the 20 mg/kg treatment group and by 34% in the 6 mg/kg treatment group [1]. |
| Synonyms | GNF-362, GNF 362 |
| Molecular Weight | 426.44 |
| Formula | C22H21F3N6 |
| Cas No. | 1003019-41-7 |
| Smiles | C[C@@H]1CN(Cc2cn[nH]c2-c2ccc(cc2)C#N)CCN1c1ccc(cn1)C(F)(F)F |
| Relative Density. | 1.38 g/cm3 (Predicted) |
| Color | White |
| Appearance | Solid |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||||||||||||
| Solubility Information | Ethanol: 40 mg/mL (93.8 mM), Sonication is recommended. DMSO: 80 mg/mL (187.60 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (7.74 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
Ethanol/DMSO
DMSO
| |||||||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.